Latest developments, patient stories, and oncology insights from Guangzhou Concord Cancer Center.
GCCC's radiotherapy physics team presented three research papers on proton therapy at the 2026 Joint AAPM|COMP Meeting in Vancouver. Prof. Yuanshui Zheng attended as the sole Chinese hospital representative on the Particle Therapy Subcommittee.
Read More →
A Cambodian oncology delegation led by Professor Dr. Eav Sokha visited Guangzhou Concord Cancer Center on July 16, 2026, touring the proton therapy center and exploring cross-border cancer care collaboration under the Health Silk Road initiative.
Read More →
A patient with advanced bilateral breast cancer and multiple metastases received multidisciplinary, stratified care at Guangzhou Concord Cancer Center, achieving tumor regression and restored quality of life.
Read More →
Guangzhou Concord Cancer Center hosted a roundtable on regional international healthcare development, exploring why patients from over 20 countries and regions choose the Greater Bay Area for cancer care.
Read More →
Guangzhou Concord Cancer Center became one of the first hospitals in China to clinically administer Iza-Bren (Yizekang), just eight days after NMPA approval.
Read More →
As the only Chinese medical institution focused on proton therapy at the exhibition, Guangzhou Concord Cancer Center attracted widespread attention from healthcare professionals across Bangladesh and South Asia. Featured in Bangladesh Sun.
Read More →
A clear, patient-friendly guide: photons are like a searchlight, protons are like a depth charge. Four questions to help you decide with your oncology team.
Read More →
Rafi, a young Indonesian man with a rare 10cm sacral chordoma, found hope at GCCC after exhausting local options. His story: surgery + proton therapy, and a team that treated him "like family."
Read More →
GCCC pioneers SpaceOAR rectal spacer in China — a 20-minute procedure creating a 1.2cm protective buffer, combined with proton therapy reducing organ radiation by 80%.
Read More →
How GCCC's Gamma Knife technology offers 80-90% effective pain relief without open surgery — a breakthrough for patients who have exhausted conventional treatments.
Read More →
After a 5-year battle with DLBCL, Ms. M traveled 2,000km from Dhaka to Guangzhou. Her verdict on GCCC's multidisciplinary care and international patient services.
Read More →
A 60-year-old patient with two primary pelvic cancers achieved pathologic complete response after synchronized proton therapy and concurrent chemotherapy at GCCC.
Read More →
365 days of clinical proton therapy: 40+ disease types, 99.2% uptime, 97.7% completion rate, and patients from 20+ countries and regions.
Read More →